Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastati...
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer
About this item
Full title
Author / Creator
Monge, Cecilia , Xie, Changqing , Myojin, Yuta , Coffman, Kelley , Hrones, Donna Mabry , Wang, Sophie , Hernandez, Jonathan M , Wood, Bradford J , Levy, Elliot B , Juburi, Israa , Hewitt, Stephen M , Kleiner, David E , Steinberg, Seth M , Figg, William D , Redd, Bernadette , Homan, Philip , Cam, Maggie , Ruf, Benjamin , Duffy, Austin G and Greten, Tim F
Publisher
England: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundOncolytic immunotherapy represents a unique therapeutic platform for the treatment of cancer. Here, we evaluated the safety and efficacy of the combination of pexastimogene devacirepvec (PexaVec) plus durvalumab (anti-programmed death ligand 1) with and without tremelimumab (anti-cytotoxic T-lymphocyte associated protein 4) in patients wi...
Alternative Titles
Full title
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer
Authors, Artists and Contributors
Author / Creator
Xie, Changqing
Myojin, Yuta
Coffman, Kelley
Hrones, Donna Mabry
Wang, Sophie
Hernandez, Jonathan M
Wood, Bradford J
Levy, Elliot B
Juburi, Israa
Hewitt, Stephen M
Kleiner, David E
Steinberg, Seth M
Figg, William D
Redd, Bernadette
Homan, Philip
Cam, Maggie
Ruf, Benjamin
Duffy, Austin G
Greten, Tim F
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_7d02b8ba4ef24ff8856cf44022b698f1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7d02b8ba4ef24ff8856cf44022b698f1
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1136/jitc-2022-005640
